Recent News

• 08.06.2026 - Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
• 07.14.2026 - Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
• 06.26.2026 - Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
• 05.15.2026 - Ensysce Biosciences Reports First Quarter 2026 Financial Results
• 05.12.2026 - Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
• 05.08.2026 - Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
• 04.16.2026 - Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
• 04.07.2026 - Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
• 03.30.2026 - Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
• 03.04.2026 - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Recent Filings

• 08.06.2026 - 8-K/A Current report
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 07.15.2026 - 8-K Current report
• 06.26.2026 - EFFECT Notice of Effectiveness
• 06.04.2026 - S-3 Registration statement under Securities Act of 1933
• 05.22.2026 - 8-K Current report
• 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2026 - 8-K Current report
• 05.15.2026 - EX-99.1 EX-99.1